A clinical trial supported by NIH found that pomalidomide, a drug previously used for bone marrow cancer and Kaposi sarcoma, is a promising treatment for Hereditary Hemorrhagic Telangiectasia (HHT). Patients taking pomalidomide experienced a significant reduction in nosebleeds, required fewer blood transfusions, and reported improved quality of life. These findings offer hope for people with HHT, a rare genetic disorder that causes excessive bleeding. While more research is needed, pomalidomide has shown promise as a safe and effective treatment option.